Bergmark B. auteur aut IRD Bergmark R. auteur aut IRD Beaudrap de Pierre auteur aut IRD Boum Y. auteur aut IRD Mwanga-Amumpaire J. auteur aut IRD Carroll R. auteur aut IRD Zapol W. auteur aut IRD text journalArticle eng text/pdf born digital access There are approximately 225-600 million new malaria infections worldwide annually, with severe and cerebral malaria representing major causes of death internationally. The role of nitric oxide (NO) in the host response in cerebral malaria continues to be elucidated, with numerous known functions relating to the cytokine, endovascular and cellular responses to infection with Plasmodium falciparum. Evidence from diverse modes of inquiry suggests NO to be critical in modulating the immune response and promoting survival in patients with cerebral malaria. This line of investigation has culminated in the approval of 2 phase II randomized prospective clinical trials in Uganda studying the use of inhaled NO as adjuvant therapy in children with severe malaria. The strategy underlying both trials is to use the sytemic antiinflammatory properties of inhaled NO to "buy time" for chemical antiparasite therapy to lower the parasite load. This article reviews the nexus of malaria and NO biology with a primary focus on cerebral malaria in humans. specialized inhaled nitric oxide cerebral malaria nitric oxide synthase Plasmodium falciparum 050 052 31 12 E250-E254 2012 0891-3668 https://www.documentation.ird.fr/hor/PAR00009527 10.1097/INF.0b013e318266c113 0891-3668 [F B010092294] https://www.documentation.ird.fr/hor/PAR00009527 https://www.documentation.ird.fr/intranet/publi/2024-11/010092294.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2013-01-09 2024-11-18 PAR00009527 fre